Publications

Find below research publications published and disseminated by the Pathfinder Foundation

Chinese, American scientists "light up" lung cancer mutations

WASHINGTON, March 7 (Xinhua) -- Chinese and American scientists have found a new way to identify non-small cell lung cancers (NSCLC), the most common type of lung cancer, non-invasively. In a study reported on Wednesday in the journal Science Translational Medicine, the scientists used a radio-labeled chemical tracer to mark certain cancer mutations, which can help determine sensitivity to and the efficacy of a therapy called tyrosine kinase inhibition in NSCLC patients. NSCLC with those mutations can be best treated with drugs called tyrosine kinase inhibitors. The inhibitors can extend median survival time of cancer patients with a mutation in the epidermal growth factor receptor or EGFR protein to greater than two years, more than twice the survival of patients receiving only chemotherapy.

  

fa    na 
Image

Pathwalker, there is no path. You must make the path as you walk - Antonio Machado

Contact Us

(+94)114 529952/3

(+94)114 529952/3

pm@pathfinderfoundation.org

pm@pathfinderfoundation.org

The Pathfinder Foundation Riverpoint 339/6, Negombo Road Peliyagoda

The Pathfinder Foundation
Riverpoint
339/6, Negombo Road
Peliyagoda

Follow Us

© 2021 Pathfinder.  All Rights Reserved.